<DOC>
	<DOCNO>NCT01170949</DOCNO>
	<brief_summary>Randomised , double-blind , placebo-controlled study evaluate effect miltefosine skin lesion patient treatment resistant chronic urticaria . Treatment resistance define insufficient treatment response minimum 1 week therapy maximum label dose non-sedating antihistamine . Eligible subject enrol baseline 8 ( +/- 1 ) day screen . 75 Patients randomise 2:1 ratio one follow treatment group add-on ongoing therapy non-sedating antihistamine treatment period 4 week : 25 placebo 50 active drug Efficacy safety evaluation do baseline day 7 , 14 , 21 safety , ) 28 ( end treatment ) day 56 ( 28 day end treatment ) .</brief_summary>
	<brief_title>Efficacy Safety Miltefosine Antihistamine Resistant Chronic Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Inclusion criterion Informed consent sign dated Outpatients moderate severe spontaneous CU define UAS ≥15 ( maximum label dose nonsedating antihistamine Resistant standard treatment antihistamine minimum 7 day therapy maximum label dose nonsedating antihistamine ( levocetirizine , cetirizine , fexofenadine , desloratadine , loratadine , ebastine , mizolastine Aged 18 year Reliable method contraception woman childbearing potential well men study 3 month thereafter . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner . Pregnancy lactation Participation another clinical trial within last 30 day Body weight ≤ 45 kg Subjects inmates psychiatric ward , prison , state institution . Existing plan placement institution rule accord § 40 passage 1 number 4 AMG ( Arzneimittelgesetz ) . Skin symptom cause primarily physical urticaria Urticaria vasculitis Known hypersensitivity miltefosine Retinal pathology Leishmaniasis Gastrointestinal disturbance may influence oral resorption ( e.g . chronic diarrhoea disease , congenital malformation major surgical resection gastrointestinal tract ) . History within 5 year presence myocardial infarction major cardiac disorder . Serumcreatinine and/or BUN 1.5 time upper reference value GOT and/or GPT and/or alkaline phosphatase 3 time upper reference value ) . SjögrenLarssonSyndrome . Malignancy within last 5 year require chemotherapy radiation therapy . Mental disorder interfere evaluation study endpoint Drug alcohol dependency Any chronic acute illness require systemic treatment might influence outcome study 4 week start treatment study ( investigator 's decision ) . Immunodeficiency include HIV During past 10 day start treatment study Topical steroid H2 antihistamine Leukotriene antagonist H1 antihistamine basic therapy During past 2 week start treatment study Ketotifen Doxepin During past 4 week start treatment study Systemic corticosteroid UV therapy include PUVA Systemic immunosuppressives include corticosteroid , immunomodulators , immunostimulants During past 12 week start treatment study Astemizole Tranquilizers , antidepressant , sedative , hypnotic , antiepileptic CNS active agent , except treatment tricyclic stable least 12 week prior screen throughout trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>urticaria</keyword>
</DOC>